GlassScriptPhysician profile
John L Welborn
NPI 1427496835
$2,529.24
in general payments reported to CMS, 2019-2025
14 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.73 · 2022: $223 · 2023: $533 · 2024: $642 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.25 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $716.14 | 2023-2025 | Brixadi |
| Indivior INC. | $434.22 | 2021-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $364.13 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $171.61 | 2024-2025 | Airsupra |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Alkermes, INC. | $139.33 | 2021-2023 | Aristada, Aristada Initio |
| Sanofi-Aventis U.S. LLC | $133.71 | 2022 | |
| Mylan Specialty L.P. | $125.00 | 2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $111.69 | 2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Gilead Sciences, INC. | $98.67 | 2022-2023 | Epclusa |
| Janssen Pharmaceuticals, INC | $26.37 | 2025 | Invega Sustenna |
| Exact Sciences Corporation | $21.06 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $19.82 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $17.49 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Welborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.